Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • Stakk Secures T-Mobile Contract to Power Super App Expansion
    Stakk Secures T-Mobile Contract to Power Super App Expansion
    • News

  • Medibank Backs Emyria with Landmark Depression Care Deal
    Medibank Backs Emyria with Landmark Depression Care Deal
    • News

  • NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    • News

  • BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    • News

  • Harris Technology eyes profitability as refurbished tech sales surge
    Harris Technology eyes profitability as refurbished tech sales surge
    • News

  • QIC Fund Backs Ark Mines with $4.5m to Accelerate Sandy Mitchell Development
    • News

  • Swift Secures $2.4m Chevron Contract to Extend Entertainment and Support Services
    Swift Secures $2.4m Chevron Contract to Extend Entertainment and Support Services
    • News

  • FBR’s tech could help reduce housing construction-related cost pressures
    FBR’s tech could help reduce housing construction-related cost pressures
    • News

  • Atomo Locks in US$410K Pascal Order as FebriDx Demand Accelerates in the US
    Atomo Locks in US$410K Pascal Order as FebriDx Demand Accelerates in the US
    • News

  • June 2025 quarter CPI no roadblock to August RBA rate cut
    June 2025 quarter CPI no roadblock to August RBA rate cut
    • News

Melodiol seeks redemption under new name and leadership, starts with a strong June quarter

  • In News
  • July 19, 2023
  • Clara Venisha
Melodiol seeks redemption under new name and leadership, starts with a strong June quarter

Three CEOs within 18 months, a serious listing breach, and an ASX censure. It seems like the stars were not so aligned for cannabis manufacturing company Creso Pharma’s past (formerly ASX: CPH), but with a fresh leadership and a recent name change to Melodiol (ASX: ME1), the Company is back to chasing its American and European dreams.

Melodiol had a strong start to the quarter, already generating $1.6 million in new unaudited revenue and confirmed purchase orders as of 17 July 2023. Just two weeks into the quarter, they’re on track to exceed the $4.7m in revenue reported in the June quarter, a record at the time.

Melodiol also reported $8.6m sales for the calendar year as of 17 July 2023, reaching a level close to the total revenue achieved in the entire year of 2022 ($8.7m) thanks to strong contributions from its 100%-owned subsidiaries Mernova Medicinal Inc and Health House International (HHI), as well as Creso Pharma Switzerland. Mernova supplies recreational cannabis products in the Canadian market, while HHI is a global medical cannabis wholesaler of GMP pharmaceutical products with operations in Australia, UK and Germany.

Though it was undisclosed how much each subsidiary contributed as per June quarter, Melodiol primarily attributed the strong start to the September quarter to HHI, considering HHI had only been acquired by Melodiol in May 2023. Melodiol previously highlighted that the acquisition and integration of HHI significantly increased the scale of its business, in which combined March quarter revenues of Melodiol and HHI represented $33.6m on an annual basis.

Commenting on the results, Melodiol CEO William Lay said: “In recent months, Melodiol has undertaken a number of steps to optimise its operations to capitalise on revenue growth opportunities. The group achieved exceptional momentum during the last quarter and we are pleased to see this continue in the early stages of Q3 FY2023.”

Lay also mentioned that the management team is actively assessing a number of opportunities that could expand the business outreach further and unlock additional value for shareholders. No further details regarding these opportunities have been provided so far.

A rocky past while still operating under Creso Pharma, the Company made national headlines when founder Adam Blumenthal stood down in November 2021 due to an ASIC and AFP raid. Creso received a formal censure from the ASX for “engaging in a serious breach of listing rules”. A censure allows the ASX to take over a company’s news ticker and speak directly to its shareholders.

The Company later appointed James Ellingford as a Director, but also made unceremonious headlines when documenting his volatile relationship with a woman 35 years his junior on TikTok. Those videos also showed bags of white powder that he later claimed as bags of flour.

Co-founder Boaz Wachtel soon took over as temporary chairman, and later on the Company began initiating a fresh start by appointing William Lay in January 2022 as new CEO and Managing Director. Lay’s responsibilities include advancing the company’s growth strategy in North America, pursuing a dual listing on NASDAQ, overseeing global operations including the Swiss division, exploring potential new markets, and ultimately distancing Creso from its tainted past.

Under Lay’s leadership, Creso Pharma officially rebranded as Melodiol, which was said to be a part of the Company’s broader strategy for further M&A opportunities in the US and other key markets. It now focuses on developing cannabis, hemp-derived and other plant based therapeutic, nutraceutical, and lifestyle products targeting global consumers.

Melodiol now continues to prioritise research and development (R&D) and regulatory pathways for novel treatments.

Moving on from the ill-fated combination of the Creso Pharma name and the actions of former Directors, is Melodiol now finally on track to get the ending that it deserves, defying all odds?

  • About
  • Latest Posts
Clara Venisha
Clara is a Business Reporter for The Sentiment.
Latest posts by Clara Venisha (see all)
  • IPO Watch: The Australian Wealth Advisory Group set for ASX entrance - December 15, 2023
  • Harris Technology gears up for Christmas as consumer electronics and household tipped to be among most popular purchases - November 27, 2023
  • Linius Technologies sprints into the US college sports with automated game highlight technology - November 23, 2023
  •  
  •  
  •  
  •  
  • Adam Blumenthal
  • asx cph
  • asx me1
  • cannabis
  • melodiol
  • Menova Medicinal
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Clara Venisha
Clara is a Business Reporter for The Sentiment.
Latest posts by Clara Venisha (see all)
  • IPO Watch: The Australian Wealth Advisory Group set for ASX entrance - December 15, 2023
  • Harris Technology gears up for Christmas as consumer electronics and household tipped to be among most popular purchases - November 27, 2023
  • Linius Technologies sprints into the US college sports with automated game highlight technology - November 23, 2023

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Clara Venisha
Clara is a Business Reporter for The Sentiment.
Latest posts by Clara Venisha (see all)
  • IPO Watch: The Australian Wealth Advisory Group set for ASX entrance - December 15, 2023
  • Harris Technology gears up for Christmas as consumer electronics and household tipped to be among most popular purchases - November 27, 2023
  • Linius Technologies sprints into the US college sports with automated game highlight technology - November 23, 2023
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.